Lundbeck Q3 2019 Financial Results
Potential to build a migraine franchise in the future with ALD1910 early-
stage PACAP² inhibitor mAb
A differentiated approach to
migraine prevention
* Highly potent and selective
humanized PACAP binding
antibody
Preclinical data¹ indicate
that PACAP² and CGRP3
have differentiated
pharmacology with respect
to migraine-associated
symptoms
Potential for mono-therapy
in non-CGRP induced
migraine or combination
therapy with eptinezumab
RAMP
VPAC1
VIP
PACAP-38
VPAC2
PAC1
Kaiser, Russo: "CGRP and migraine: Could PACAP play a role too?", Neuropeptides, Volume 47, Issue 6, 2013
1) Loomis et al: Pharmacologic characterization of ALD1910, a potent humanized monoclonal antibody against the pituitary adenylate
cyclase-activating peptide, JPET Fast Forward
2) Pituitary adenylate cyclase-activating peptide
3) Calcitonin gene-related peptide
38
LundbeckView entire presentation